News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
JPMorgan Chase & Co. has lowered its price target for Syndax Pharmaceuticals (NASDAQ:SNDX) from $44.00 to $40.00, while maintaining an "overweight" rating. Despite the reduced target, the average analyst rating for SNDX remains "Moderate Buy" with a consensus price target of $41.91, suggesting significant …
Syndax Pharmaceuticals (SNDX) has seen a 63.5% gain over the past year, but its current share price of US$20.40 appears stretched based on valuation metrics. Despite pipeline progress, the stock's P/S ratio of 7.2x is above its tailored fair P/S of 3.4x, suggesting it …
Hennion & Walsh Asset Management Inc. significantly increased its stake in Syndax Pharmaceuticals, Inc. by 59.6% in Q2 2026, now holding 342,883 shares valued at approximately $7.5 million. This increase comes alongside other institutional investments and recent insider stock sales by the CMO and …
This page provides financial data for Syndax Pharmaceuticals Inc (HAM:1T3), specifically focusing on its long-term debt to total assets ratio. It appears to be a financial data portal, offering an overview of the company's financials, although the specific ratio value is not displayed in …
This article provides financial data for Syndax Pharmaceuticals Inc, traded on the Hamburg Stock Exchange under the ticker 1T3. It specifically references the "Price to sales forward" metric. The page appears to be a financial data portal, showing various market data and financial tools.
This page provides financial data, specifically operating expenses (excluding COGS), for Syndax Pharmaceuticals Inc, trading under the symbol 1T3 on the Hamburg Stock Exchange. The content appears to be a financial data snippet from TradingView, indicating that specific figures are available for different periods.
The article focuses on the net margin percentage of Syndax Pharmaceuticals Inc, traded under the HAM:1T3 symbol on the Hamburg Stock Exchange. It appears to be a stub or a financial data page from TradingView, indicating that the market was closed with no trades …
State Street Corporation has reported a significant ownership stake in Syndax Pharmaceuticals Inc., holding 5,658,465 shares of common stock, which represents 6.4% of the class as of June 30, 2026. The filing, a SCHEDULE 13G, indicates that State Street exercises shared voting power over …
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) recently reported its quarterly earnings, with revenues missing analyst predictions and a larger-than-forecast statutory loss per share. Following these results, analysts have trimmed their revenue forecasts for 2026 and expect an increase in per-share losses, though the consensus price target …
Syndax Pharmaceuticals announced it granted inducement stock option awards for up to 59,250 shares to five new employees on August 1, 2026, under its 2023 Inducement Plan. These options will vest over four years, with 25% vesting after one year and the remainder vesting …
Syndax Pharmaceuticals (SNDX) saw its stock climb 4.4% following Q2 earnings that showed significant revenue growth, with sales reaching US$72.8 million for the quarter. While the company's Q2 net loss narrowed to US$49.36 million and management reiterated a funded balance sheet for late-stage programs, …
Analyst estimates for Syndax Pharmaceuticals, Inc. (SNDX) show a revised average 12-month price target of $38.27, down from $39.45, with a range between $26 and $57. This new target suggests a potential upside of approximately 101% from its Aug. 4 closing price. The consensus …
Syndax Pharmaceuticals (NASDAQ:SNDX) shares gapped down following a disappointing earnings announcement, missing EPS and revenue estimates despite significant year-over-year revenue growth. Analyst sentiment remains largely positive with a "Moderate Buy" rating, though some price targets were adjusted. Insider selling occurred, but institutional investors like …
Syndax Pharmaceuticals announced inducement awards for five new employees to purchase up to 59,250 shares of common stock under its 2023 Inducement Plan. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months, …
BofA Securities has lowered its price target for Syndax Pharmaceuticals (NASDAQ:SNDX) to $26 from $29, while maintaining a Buy rating. This adjustment follows a disappointing second-quarter report where the company missed both revenue and earnings expectations, with Revuforj sales falling below estimates. Despite these …
Sei Investments Co. increased its stake in Syndax Pharmaceuticals, Inc. by 36.3% during the first quarter, now owning 217,600 shares valued at approximately $5.1 million. Despite a recent quarterly loss and missing revenue estimates, analyst sentiment for Syndax Pharmaceuticals remains largely positive, with a …
Syndax Pharmaceuticals reported strong commercial growth in Q2 2026, with combined revenue from Revuforj and Niktimvo reaching $115 million. Revuforj sales increased 91% year-over-year, driven by increased treatment duration, while Niktimvo grew 67% year-over-year, expanding its market share in chronic GVHD. The company also …
Syndax Pharmaceuticals (SNDX) reported strong Q2 2026 results with surging revenue of US$72.79 million and narrowed net losses. The company more than doubled revenue in the first half of 2026, reaching US$137.65 million, indicating improved operating efficiency. This performance supports the investment narrative around …
Syndax Pharmaceuticals (SNDX) reported a 92% year-over-year revenue surge to $72.8 million in Q2 2026, driven by strong sales of Revuforjo and Niktimvo. Despite some fluctuations in new patient starts for Revuforjo and flattening sequential growth for Niktimvo, the company maintains a robust cash …
Syndax Pharmaceuticals (NASDAQ: SNDX) reported its second-quarter earnings, missing analyst estimates for EPS by $0.07 with a reported $-0.55 per share, and falling short on revenue with $73M against an estimated $79.8M. The company's stock price has shown a significant increase over the past …
Syndax Pharmaceuticals (SNDX) reported a Q2 loss of $0.55 per share, missing the Zacks Consensus Estimate of a $0.45 loss, and revenues of $72.79 million, falling short of estimates by 11.16%. Despite the recent underperformance, the company holds a Zacks Rank #2 (Buy), indicating …
Syndax Pharmaceuticals (SNDX) reported a significant 92% year-over-year revenue increase in Q2 2026, driven by strong sales of Revuforj and Niktimvo. The company also saw a narrowing net loss and expanded its pipeline with two new assets. SNDX maintains robust liquidity to support its …
Syndax Pharmaceuticals reported strong financial results for Q2 2026, with total revenue of $73 million, a 92% year-over-year increase, driven by significant growth in both Revuforj and Niktimvo net revenues. The company also expanded its pipeline with two new assets and anticipates topline data …
This article from Stock Traders Daily provides a detailed analysis of Syndax Pharmaceuticals Inc. (SNDX), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated institutional trading strategies, including position trading, momentum breakout, and risk hedging, tailored for different risk …
Syndax Pharmaceuticals Inc (SNDX) has a financial score of 8.24, placing it 52nd out of 385 companies in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue surged by 223.64% year-over-year to $64.86M, …
Syndax Pharmaceuticals Inc (SNDX) currently has an institutional shareholding score of 10.00, placing it first among 385 companies in the Biotechnology & Medical Research industry. The total institutional shareholding proportion has increased by 3.63% quarter-over-quarter, reaching 123.04%. Steven Cohen is the largest institutional shareholder, …
Bank of New York Mellon Corp reduced its stake in Syndax Pharmaceuticals Inc. by 8.2% in the first quarter, selling over 89,000 shares but still retaining more than 1 million shares valued at $23.5 million. Despite insider selling, analysts maintain a "Moderate Buy" rating …
Eversept Partners LP reduced its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 12.9% in the first quarter, yet it remains their 6th largest position, valued at approximately $67.4 million. Despite insider selling, analyst sentiment is a "Moderate Buy" with an average price target of $42.55. …
Syndax Pharmaceuticals (Nasdaq: SNDX) announced it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026. The company's management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results …
Syndax Pharmaceuticals will announce its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results. A replay of the event …
Search by ticker symbol or company name and select a result to open its chart.